{"id":55907,"date":"2026-01-30T13:36:45","date_gmt":"2026-01-30T05:36:45","guid":{"rendered":"https:\/\/flcube.com\/?p=55907"},"modified":"2026-01-30T13:36:46","modified_gmt":"2026-01-30T05:36:46","slug":"ascletis-asc40-phase-iii-success-in-acne-vulgaris","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55907","title":{"rendered":"Ascletis ASC40 Phase III Success in Acne Vulgaris"},"content":{"rendered":"\n<p><strong>Ascletis Pharma Inc<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1672:HKG\">HKG: 1672<\/a>) announced positive top\u2011line results from the open\u2011label <strong>Phase\u202fIII study (NCT06248008)<\/strong> for <strong>ASC40<\/strong> in <strong>moderate\u2011to\u2011severe acne vulgaris<\/strong>. The drug, a <strong>first\u2011in\u2011class fatty acid synthase (FASN) inhibitor<\/strong>, demonstrated efficacy by targeting excessive sebum production, a primary driver of acne formation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-study-results-amp-mechanism-of-action\">Study Results &amp; Mechanism of Action<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Ascletis Pharma Inc (HKEX.1672)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>ASC40 (orally bioavailable FASN inhibitor)<\/td><\/tr><tr><td><strong>Study<\/strong><\/td><td>Phase\u202fIII, open\u2011label (NCT06248008)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate\u2011to\u2011severe acne vulgaris<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Inhibits sebum production via suppression of de novo lipogenesis (DNL) in sebocytes<\/td><\/tr><tr><td><strong>Additional Effects<\/strong><\/td><td>Reduces cytokine secretion and Th17 differentiation, inhibiting inflammation<\/td><\/tr><tr><td><strong>Licensing<\/strong><\/td><td>Exclusive Greater China rights from Sagimet Biosciences (Feb\u202f2019)<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First\u2011in\u2011class FASN inhibitor targeting acne pathogenesis at metabolic source<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-position\">Strategic Context &amp; Market Position<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Acne Market Need:<\/strong> Moderate\u2011to\u2011severe acne affects <strong>30\u201350\u202fmillion patients<\/strong> in Greater China; current treatments (retinoids, antibiotics) have limited efficacy and significant side\u2011effect profiles<\/li>\n\n\n\n<li><strong>Sebum Targeting:<\/strong> ASC40 addresses <strong>excessive sebum production<\/strong>, a root cause rather than downstream inflammation, offering disease\u2011modifying potential<\/li>\n\n\n\n<li><strong>Licensing Validation:<\/strong> The <strong>2019 Sagimet deal<\/strong> provided Ascletis with exclusive development, manufacturing, and commercialization rights, positioning the company as the primary beneficiary of global FASN inhibitor innovation<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Success in acne supports potential expansion into other sebum\u2011related disorders and metabolic skin diseases<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a5800\u202fmillion\u20131.2\u202fbillion<\/strong> (US$110\u2013170\u202fmillion) peak annual sales in Greater China by 2029, based on premium pricing and first\u2011in\u2011class positioning<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> No approved oral therapies specifically target sebum production; ASC40 offers differentiation versus topical retinoids and systemic isotretinoin<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Positive Phase\u202fIII data positions Ascletis to submit <strong>New Drug Application (NDA)<\/strong> in <strong>H2\u202f2026<\/strong>; priority review possible given novel mechanism<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Validates Ascletis\u2019 strategy of in\u2011licensing first\u2011in\u2011class assets and advancing them through China\u2019s regulatory pathway<\/li>\n\n\n\n<li><strong>Global Opportunity:<\/strong> Sagimet retains ex\u2011China rights; Ascletis\u2019 success may accelerate global development and partnership opportunities<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Complete Phase\u202fIII data analysis; NDA submission to NMPA targeted for <strong>Q3\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory submissions, and commercial expectations for ASC40. Actual results may differ due to NMPA review processes, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ascletis Pharma Inc (HKG: 1672) announced positive top\u2011line results from the open\u2011label Phase\u202fIII study (NCT06248008)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55909,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[11],"tags":[189,980,25],"class_list":["post-55907","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-drug","tag-ascletis-pharma","tag-hkg-1672","tag-potential-first-in-class"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascletis ASC40 Phase III Success in Acne Vulgaris - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ascletis Pharma Inc (HKG: 1672) announced positive top\u2011line results from the open\u2011label Phase\u202fIII study (NCT06248008) for ASC40 in moderate\u2011to\u2011severe acne vulgaris. The drug, a first\u2011in\u2011class fatty acid synthase (FASN) inhibitor, demonstrated efficacy by targeting excessive sebum production, a primary driver of acne formation.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55907\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascletis ASC40 Phase III Success in Acne Vulgaris\" \/>\n<meta property=\"og:description\" content=\"Ascletis Pharma Inc (HKG: 1672) announced positive top\u2011line results from the open\u2011label Phase\u202fIII study (NCT06248008) for ASC40 in moderate\u2011to\u2011severe acne vulgaris. The drug, a first\u2011in\u2011class fatty acid synthase (FASN) inhibitor, demonstrated efficacy by targeting excessive sebum production, a primary driver of acne formation.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55907\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-30T05:36:45+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-30T05:36:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3010.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55907#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55907\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascletis ASC40 Phase III Success in Acne Vulgaris\",\"datePublished\":\"2026-01-30T05:36:45+00:00\",\"dateModified\":\"2026-01-30T05:36:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55907\"},\"wordCount\":382,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55907#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3010.webp\",\"keywords\":[\"Ascletis Pharma\",\"HKG: 1672\",\"Potential first-in-class\"],\"articleSection\":[\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55907#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55907\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55907\",\"name\":\"Ascletis ASC40 Phase III Success in Acne Vulgaris - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55907#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55907#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3010.webp\",\"datePublished\":\"2026-01-30T05:36:45+00:00\",\"dateModified\":\"2026-01-30T05:36:46+00:00\",\"description\":\"Ascletis Pharma Inc (HKG: 1672) announced positive top\u2011line results from the open\u2011label Phase\u202fIII study (NCT06248008) for ASC40 in moderate\u2011to\u2011severe acne vulgaris. The drug, a first\u2011in\u2011class fatty acid synthase (FASN) inhibitor, demonstrated efficacy by targeting excessive sebum production, a primary driver of acne formation.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55907#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55907\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55907#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3010.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/3010.webp\",\"width\":1080,\"height\":608,\"caption\":\"Ascletis ASC40 Phase III Success in Acne Vulgaris\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55907#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascletis ASC40 Phase III Success in Acne Vulgaris\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascletis ASC40 Phase III Success in Acne Vulgaris - Insight, China&#039;s Pharmaceutical Industry","description":"Ascletis Pharma Inc (HKG: 1672) announced positive top\u2011line results from the open\u2011label Phase\u202fIII study (NCT06248008) for ASC40 in moderate\u2011to\u2011severe acne vulgaris. The drug, a first\u2011in\u2011class fatty acid synthase (FASN) inhibitor, demonstrated efficacy by targeting excessive sebum production, a primary driver of acne formation.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55907","og_locale":"en_US","og_type":"article","og_title":"Ascletis ASC40 Phase III Success in Acne Vulgaris","og_description":"Ascletis Pharma Inc (HKG: 1672) announced positive top\u2011line results from the open\u2011label Phase\u202fIII study (NCT06248008) for ASC40 in moderate\u2011to\u2011severe acne vulgaris. The drug, a first\u2011in\u2011class fatty acid synthase (FASN) inhibitor, demonstrated efficacy by targeting excessive sebum production, a primary driver of acne formation.","og_url":"https:\/\/flcube.com\/?p=55907","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-30T05:36:45+00:00","article_modified_time":"2026-01-30T05:36:46+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3010.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55907#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55907"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascletis ASC40 Phase III Success in Acne Vulgaris","datePublished":"2026-01-30T05:36:45+00:00","dateModified":"2026-01-30T05:36:46+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55907"},"wordCount":382,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55907#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3010.webp","keywords":["Ascletis Pharma","HKG: 1672","Potential first-in-class"],"articleSection":["Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55907#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55907","url":"https:\/\/flcube.com\/?p=55907","name":"Ascletis ASC40 Phase III Success in Acne Vulgaris - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55907#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55907#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3010.webp","datePublished":"2026-01-30T05:36:45+00:00","dateModified":"2026-01-30T05:36:46+00:00","description":"Ascletis Pharma Inc (HKG: 1672) announced positive top\u2011line results from the open\u2011label Phase\u202fIII study (NCT06248008) for ASC40 in moderate\u2011to\u2011severe acne vulgaris. The drug, a first\u2011in\u2011class fatty acid synthase (FASN) inhibitor, demonstrated efficacy by targeting excessive sebum production, a primary driver of acne formation.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55907#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55907"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55907#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3010.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3010.webp","width":1080,"height":608,"caption":"Ascletis ASC40 Phase III Success in Acne Vulgaris"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55907#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascletis ASC40 Phase III Success in Acne Vulgaris"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/3010.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55907"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55907\/revisions"}],"predecessor-version":[{"id":55910,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55907\/revisions\/55910"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55909"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55907"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55907"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}